Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide Acetate in Advanced Hepatocellular Carcinoma
NCT00257426Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jul 2005
- Primary completion
- Feb 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of octreotide in hepatocellular carcinoma (HCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Overall Survival at 6 months. Started Jul 2005; status: completed.
02
Drugs
octreotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00257426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257426.